Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 10/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Papaverine SCHEMBL34702 | 1.00 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL9551009 | 1.00 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29360983 | 1.00 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL28169527 | 0.99 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29696479 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL8691148 | 0.99 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL677440 | 0.99 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29356374 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL9614479 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL5500363 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12175886-B2 | Fake blood for use in simulated surgical procedures | Intuitive Surgical Operations, Inc. (US) | 2024-12-24 | — | — | US | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | claimed |
| US-20230126091-A1 | FAKE BLOOD FOR USE IN SIMULATED SURGICAL PROCEDURES | Intuitive Surgical Operations, Inc. | 2023-04-27 | — | — | US | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | claimed |
| US-12635625-B2 | Bioceramic and carbon-based hydroponic systems, methods and devices | MULTIPLE ENERGY TECHNOLOGIES LLC | 2026-05-26 | — | — | US | disclosed |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4714496-A2 | TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | OrfoNeuro ApS (DK) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077027-A1 | PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577282-B2 | Galectin-1/ galectin-3 chimeras and multivalent proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-17 | — | — | US | disclosed |
| US-11324758-B2 | Formulation and process for limiting nerve trauma | INTRAVITAL PTY LTD (AU) | 2022-05-10 | — | — | US | disclosed |
| WO-2022076932-A1 | COMPOSITIONS AND METHODS OF TREATING A PI3K MEDIATED DISEASE | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022072348-A1 | STROKE TREATMENT | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-04-07 | — | — | WO | disclosed |
| US-20220106580-A1 | TARGETED CHONDROITINASE ABC FUSION PROTEINS AND COMPLEXES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220098258-A1 | GALECTIN-1/ GALECTIN-3 CHIMERAS AND MULTIVALENT PROTEINS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-03-31 | — | — | US | disclosed |
| CN-108366947-B | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2022036063-A2 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577282-B2 | Galectin-1/ galectin-3 chimeras and multivalent proteins | LGALS1, LGALS3BP, LGALS3 | PDE10A 3466/4885PDE3A 2960/4885PDE3B 2702/4885 |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, TERT, BRCA1 | PDE10A 4558/4885PDE3A 4521/4885PDE3B 4623/4885 |
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | RNMT, NSUN2, FBL | PDE10A 3909/4885PDE3A 4353/4885PDE3B 4422/4885 |
| US-12635625-B2 | Bioceramic and carbon-based hydroponic systems, methods and devices | CNR2, WNT1, CNR1 | PDE10A 1829/4885PDE3A 3582/4885PDE3B 4292/4885 |
| US-20260077027-A1 | PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES | MICA, PDCD1LG2, TLR9 | PDE10A 4246/4885PDE3A 4571/4885PDE3B 4410/4885 |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | PDE10A 957/4885PDE3A 1429/4885PDE3B 1494/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | PDE10A 957/4885PDE3A 1429/4885PDE3B 1494/4885 |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | FLNB, FLNA, DAGLB | PDE10A 340/4885PDE3A 1371/4885PDE3B 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.